Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 15, 2025 10:21 ET | Source: KuicK Research

DLL3 Targeted Therapy Market Size DLL3 Drugs Clinical Trials DLL3 Cancer Therapy Market Drugs Approval Insight

Delhi, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Global DLL3 Targeted Therapies Market, Approved Drugs Dosage, Pricing & Clinical Trials Insight 2025 Report Finding and Highlights: Global &...
December 19, 2023 07:30 ET | Source: Harpoon Therapeutics Inc.

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
November 09, 2023 16:01 ET | Source: Harpoon Therapeutics Inc.

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung...
May 02, 2022 09:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...
March 07, 2022 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
June 04, 2021 16:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
April 10, 2021 08:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
January 04, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 06, 2019 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC® product candidates in development for the treatment of prostate and ovarian...
October 29, 2019 12:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) --...